Targeted Drug Delivery for Challenging Oncology Therapeutics
NanoCage Bio is developing a protein nanocage platform designed to improve the intracellular delivery, targeting, and efficacy of therapeutic candidates while reducing off-target toxicity.
Drug Delivery Limits the Potential of Oncology Therapeutics
Many promising cancer therapeutics fail not because they lack activity, but because they cannot be effectively delivered to the right place in the body.
Key challenges include:
Poor targeting to tumour cells
Degradation before reaching the site of action
Extremely low accumulation in solid tumours
Off-target toxicity and side effects
Notably, less than 10% of anticancer drugs reach their target tumour tissue, significantly limiting therapeutic impact.
These challenges lead to failed or underperforming drug candidates, increasing cost and slowing progress in oncology.
Help Us Understand Your Drug Delivery Challenges
We’re currently exploring how this technology could support real-world drug development.
Your input will help us understand:
- Where delivery challenges are most critical
- How this technology could be applied
- Potential collaboration or licensing opportunities
A Protein Nanocage Platform for Targeted Delivery
NanoCage Bio is developing a drug delivery platform designed to improve how therapeutics are formulated, delivered, and released.
Our approach focuses on:
Encapsulating therapeutic cargo up to ~20kDa to improve stability and formulation
Targeting disease-specific biomarkers to improve delivery to cancer cells
Reducing off-target toxicity
Protecting drugs from degradation during circulation
Enabling intracellular release of therapeutics
This approach aims to enhance the effectiveness of existing and emerging oncology therapeutics.
Who This Is Relevant For
We are currently speaking with pharmaceutical and biotechnology organisations developing oncology therapeutics.
This may be particularly relevant if you are working on drug candidates that face challenges with:
- Delivery to target cells
- Toxicity or off-target effects
- Stability or formulation
Get in Touch
We are currently exploring how this technology could be applied to real-world drug development challenges.
If you are working on oncology therapeutics and are interested in improving delivery, targeting, or efficacy, we would welcome a conversation.
Contact Details
Dr Antonia Molloy
📧 antonia.molloy@nottingham.ac.uk